Srinivasan Yegnasubramanian

Srinivasan Yegnasubramanian

Auto-generated profile, based on publicly available information

Srinivasan Yegnasubramanian

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Nature
Verified
Journal Article
Open access
PDF file
JCJustina X. Caushi
Justina X. Caushi
JZJiajia Zhang
Jiajia Zhang
ZJZhicheng Ji
Zhicheng Ji
AVAjay Vaghasia
Ajay Vaghasia
BZBoyang Zhang
Boyang Zhang
KSKellie N. Smith
Kellie N. Smith
PD-1 blockade unleashes CD8 T cells1, including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell responses. Single-cell transcriptomics have revealed global T cell dysfunction programs in tumour-infiltrating lymphocytes (TIL). However, the majority of TIL do not recognize tumour antigens2, and little is known about transcriptional programs of MANA-specific TIL. Here, we identify MANA-specific T cell clones using the MANA functional expansion of specific T cells assay3in neoadjuvant anti-PD-1-treated non-small cell lung cancers (NSCLC). We use their T cell receptors as a ‘barcode’ to track and analyse their transcriptional programs in the tumour microenvironment using coupled single-cell RNA sequencing and T cell receptor sequencing. We find both MANA- and virus-specific clones in TIL, regardless of response, and MANA-, influenza- and Epstein–Barr virus-specific TIL each have unique transcriptional programs. Despite exposure to cognate antigen, MANA-specific TIL express an incompletely activated cytolytic program. MANA-specific CD8 T cells have hallmark transcriptional programs of tissue-resident memory (TRM) cells, but low levels of interleukin-7 receptor (IL-7R) and are functionally less responsive to interleukin-7 (IL-7) compared with influenza-specific TRM cells. Compared with those from responding tumours, MANA-specific clones from non-responding tumours express T cell receptors with markedly lower ligand-dependent signalling, are largely confined to HOBIThighTRM subsets, and coordinately upregulate checkpoints, killer inhibitory receptors and inhibitors of T cell activation. These findings provide important insights for overcoming resistance to PD-1 blockade.

4 July 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MHMichael C Haffner
Michael C Haffner
MAMartin J Aryee
Martin J Aryee
ATAntoun Toubaji
Antoun Toubaji
DEDavid M Esopi
David M Esopi
RARoula Albadine
Roula Albadine
SYSrinivasan Yegnasubramanian
Srinivasan Yegnasubramanian
Srinivasan Yegnasubramanian and colleagues show that androgen signaling promotes recruitment of androgen receptor and TOP2B to sites of TMPRSS2-ERG genomic breakpoints, triggering TOP2B-mediated double-strand breaks. These findings provide insights into the mechanism underlying this common prostate cancer gene fusion event. DNA double-strand breaks (DSBs) can lead to the development of genomic rearrangements, which are hallmarks of cancer. Fusions between TMPRSS2, encoding the transmembrane serine protease isoform 2, and ERG, encoding the v-ets erythroblastosis virus E26 oncogene homolog, are among the most common oncogenic rearrangements observed in human cancer. We show that androgen signaling promotes co-recruitment of androgen receptor and topoisomerase II beta (TOP2B) to sites of TMPRSS2-ERG genomic breakpoints, triggering recombinogenic TOP2B-mediated DSBs. Furthermore, androgen stimulation resulted in de novo production of TMPRSS2-ERG fusion transcripts in a process that required TOP2B and components of the DSB repair machinery. Finally, unlike normal prostate epithelium, prostatic intraepithelial neoplasia cells showed strong coexpression of androgen receptor and TOP2B. These findings implicate androgen-induced TOP2B-mediated DSBs in generating TMPRSS2-ERG rearrangements.

16 December 2020 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
MHMichael C. Haffner
Michael C. Haffner
WZWilbert Zwart
Wilbert Zwart
MRMartine P. Roudier
Martine P. Roudier
LTLawrence D. True
Lawrence D. True
WNWilliam G. Nelson
William G. Nelson
SYSrinivasan Yegnasubramanian
Srinivasan Yegnasubramanian

25 October 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MHMichael C Haffner
Michael C Haffner
TMTimothy Mosbruger
Timothy Mosbruger
DEDavid M Esopi
David M Esopi
HFHelen Fedor
Helen Fedor
CHChristopher M Heaphy
Christopher M Heaphy
SYSrinivasan Yegnasubramanian
Srinivasan Yegnasubramanian
Recent controversies surrounding prostate cancer overtreatment emphasize the critical need to delineate the molecular features associated with progression to lethal metastatic disease. Here, we have used whole-genome sequencing and molecular pathological analyses to characterize the lethal cell clone in a patient who died of prostate cancer. We tracked the evolution of the lethal cell clone from the primary cancer to metastases through samples collected during disease progression and at the time of death. Surprisingly, these analyses revealed that the lethal clone arose from a small, relatively low-grade cancer focus in the primary tumor, and not from the bulk, higher-grade primary cancer or from a lymph node metastasis resected at prostatectomy. Despite being limited to one case, these findings highlight the potential importance of developing and implementing molecular prognostic and predictive markers, such as alterations of tumor suppressor proteins PTEN or p53, to augment current pathological evaluation and delineate clonal heterogeneity. Furthermore, this case illustrates the potential need in precision medicine to longitudinally sample metastatic lesions to capture the evolving constellation of alterations during progression. Similar comprehensive studies of additional prostate cancer cases are warranted to understand the extent to which these issues may challenge prostate cancer clinical management.

31 August 2011 in Oncotarget
Verified
Journal Article
Open access
PDF file
MHMichael Christoph Haffner
Michael Christoph Haffner
ACAlcides Chaux
Alcides Chaux
AMAlan K. Meeker
Alan K. Meeker
DEDavid M. Esopi
David M. Esopi
JGJonathan Gerber
Jonathan Gerber
SYSrinivasan Yegnasubramanian
Srinivasan Yegnasubramanian
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers

23 January 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MAMartin J. Aryee
Martin J. Aryee
WLWennuan Liu
Wennuan Liu
JEJulia Engelmann
Julia Engelmann
PNPhilipp Nuhn
Philipp Nuhn
MGMeltem Gurel
Meltem Gurel
SYSrinivasan Yegnasubramanian
Srinivasan Yegnasubramanian
Prostate tumors develop a unique epigenetic DNA methylation signature that is clonally maintained in disseminated metastases.